Don't mind me, I'm just collecting links.
Testimonial: "I cannot see a slither of a viable defense for this godawful circlejerk board."
This section allows you to view all posts made by this member. Note that you can only see posts made in areas you currently have access to.
The post by Maine People’s Alliance activist Mike Tipping mined press clippings to unearth several offensive comments. In one, Lockman implied that HIV and AIDS could be spread by bed sheets and mosquitoes. In another, he said that the progressive movement assisted the AIDS epidemic by assuring “the public that the practice of sodomy is a legitimate alternative lifestyle, rather than a perverted and depraved crime against humanity.” In a 1995 letter in the Sun Journal in Lewiston, a reader quoted a press statement by Lockman, then part of the Pro Life Education Association, saying, “If a woman has (the right to an abortion), why shouldn’t a man be free to use his superior strength to force himself on a woman? At least the rapist’s pursuit of sexual freedom doesn’t (in most cases) result in anyone’s death.”
Paradoxically the hottest fields, with the most people pursuing the same questions, are most prone to error, Dr. Ioannidis argued. If one of five competing labs is alone in finding an effect, that result is the one likely to be published. But there is a four in five chance that it is wrong. Papers reporting negative conclusions are more easily ignored.
Putting all of this together, Dr. Ioannidis devised a mathematical model supporting the conclusion that most published findings are probably incorrect.
Other scientists have questioned whether his methodology was skewed by his own biases. But the same year he published another blockbuster, examining more than a decade’s worth of highly regarded papers — the effect of a daily aspirin on cardiac disease, for example, or the risks of hormone replacement therapy for older women. He found that a large proportion of the conclusions were undermined or contradicted by later studies.
His work was just the beginning. Concern about the problem has reached the point that the journal Nature has assembled an archive, filled with reports and analyses, called Challenges in Irreproducible Research.
Among them is a paper in which C. Glenn Begley, who is chief scientific officer at TetraLogic Pharmaceuticals, described an experience he had while at Amgen, another drug company. He and his colleagues could not replicate 47 of 53 landmark papers about cancer. Some of the results could not be reproduced even with the help of the original scientists working in their own labs.